Patents by Inventor Fergus Couch

Fergus Couch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chromosome 13-linked breast cancer susceptibility gene
    Patent number: 6124104
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast cancer predisposing gene (BRCA2), some mutant alleles of which cause susceptibility to cancer, in particular breast cancer. More specifically, the invention relates to germline mutations in the BRCA2 gene and their use in the diagnosis of predisposition to breast cancer. The present invention further relates to somatic mutations in the BRCA2 gene in human breast cancer and their use in the diagnosis and prognosis of human breast cancer. Additionally, the invention relates to somatic mutations in the BRCA2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA2 gene, including gene therapy, protein replacement therapy and protein mimetics.
    Type: Grant
    Filed: March 20, 1998
    Date of Patent: September 26, 2000
    Assignees: Myriad Genectics, Inc., Endo Recherche, Inc., HSC Reseach & Development Limited Partnership, Trustees of the University of Pennsylvania
    Inventors: Sean V. Tavtigian, Alexander Kamb, Jacques Simard, Fergus Couch, Johanna M. Rommens, Barbara L. Weber
  • Chromosome 13-linked breast cancer susceptibility gene
    Patent number: 6033857
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast cancer predisposing gene (BRCA2), some mutant alleles of which cause susceptibility to cancer, in particular breast cancer. More specifically, the invention relates to germline mutations in the BRCA2 gene and their use in the diagnosis of predisposition to breast cancer. The present invention further relates to somatic mutations in the BRCA2 gene in human breast cancer and their use in the diagnosis and prognosis of human breast cancer. Additionally, the invention relates to somatic mutations in the BRCA2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA2 gene, including gene therapy, protein replacement therapy and protein mimetics.
    Type: Grant
    Filed: March 20, 1998
    Date of Patent: March 7, 2000
    Assignees: Myriad Genetics, Inc., Endo Recherche, Inc., HSC Research & Development Limited Parntership, Trustees of the Univ. of Pennsylvania
    Inventors: Sean V. Tavtigian, Alexander Kamb, Jacques Simard, Fergus Couch, Johanna M. Rommens, Barbara L. Weber
  • Chromosome 13-linked breast cancer susceptibility gene
    Patent number: 5837492
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast cancer predisposing gene (BRCA2), some mutant alleles of which cause susceptibility to cancer, in particular breast cancer. More specifically, the invention relates to germline mutations in the BRCA2 gene and their use in the diagnosis of predisposition to breast cancer. The present invention further relates to somatic mutations in the BRCA2 gene in human breast cancer and their use in the diagnosis and prognosis of human breast cancer. Additionally, the invention relates to somatic mutations in the BRCA2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA2 gene, including gene therapy, protein replacement therapy and protein mimetics.
    Type: Grant
    Filed: April 29, 1996
    Date of Patent: November 17, 1998
    Assignees: Myriad Genetics, Inc., Endo Recherche, Inc., HSC Research & Development Limited Partnership, Trustees of the University of Pennsylvaina
    Inventors: Sean V. Tavtigian, Alexander Kamb, Jacques Simard, Fergus Couch, Johanna M. Rommens, Barbara L. Weber